Catalog No.
YVV03201
Expression system
E. coli
Species
Human immunodeficiency virus 2 (HIV-2)
Protein length
Gln547-Tyr670
Predicted molecular weight
14.91 kDa
Nature
Recombinant
Endotoxin level
Please contact with the lab for this information.
Purity
>90% as determined by SDS-PAGE.
Accession
L8B302
Applications
ELISA, Immunogen, SDS-PAGE, WB, Bioactivity testing in progress
Form
Lyophilized
Storage buffer
Lyophilized from a solution in PBS pH 7.4, 0.02% NLS, 1mM EDTA, 4% Trehalose, 1% Mannitol.
Reconstitution
Reconstitute in sterile water for a stock solution. A copy of datasheet will be provided with the products, please refer to it for details.
Shipping
In general, proteins are provided as lyophilized powder/frozen liquid. They are shipped out with dry ice/blue ice unless customers require otherwise.
Stability and Storage
Use a manual defrost freezer and avoid repeated freeze thaw cycles. Store at 2 to 8°C for frequent use. Store at -20 to -80°C for twelve months from the date of receipt.
Alternative Names
Envelope glycoprotein gp160, Transmembrane protein gp41, TM, env, gp36
HIV-2 Neutralization Sensitivity in Relation to Co-Receptor Entry Pathways and Env Motifs. PMID: 35563157
Molecular epidemiology of HIV. PMID: 15817947
Determinants in HIV-2 Env and tetherin required for functional interaction. PMID: 26248668
Intra-Patient Evolution of HIV-2 Molecular Properties. PMID: 36366545
HIV-1 Vpu and HIV-2 Env counteract BST-2/tetherin by sequestration in a perinuclear compartment. PMID: 20529266
Study of the HIV-2 Env cytoplasmic tail variability and its impact on Tat, Rev and Nef. PMID: 24223892
Antagonism of BST-2/Tetherin Is a Conserved Function of the Env Glycoprotein of Primary HIV-2 Isolates. PMID: 27681141
Single Amino Acid Substitution N659D in HIV-2 Envelope Glycoprotein (Env) Impairs Viral Release and Hampers BST-2 Antagonism. PMID: 27754450
Bacterially produced HIV-2 env polypeptides specific for distinguishing HIV-2 from HIV-1 infections. PMID: 2187502
Cost-effective diagnosis of HIV-1 and HIV-2 by recombinant-expressed env peptide (566/996) dot-blot analysis. PMID: 8507413
Intrahost evolution of the HIV-2 capsid correlates with progression to AIDS. PMID: 36533148
The env protein of an infectious noncytopathic HIV-2 is deficient in syncytium formation. PMID: 2364016
How does the humoral response to HIV-2 infection differ from HIV-1 and can this explain the distinct natural history of infection with these two human retroviruses? PMID: 25445493
Multispot HIV-1/HIV-2 Rapid Test: advantages over other rapid HIV tests. PMID: 17892358
HIV-2 diversity displays two clades within group A with distinct geographical distribution and evolution. PMID: 34422316
Recombinant peptides derived from the env-gene of HIV-2 in the serodiagnosis of HIV-2 infections. PMID: 2496732
HIV-1/HIV-2 seronegativity in HIV-1 subtype O infected patients. PMID: 7910884
Introduction of HIV-2 and multiple HIV-1 subtypes to Lebanon. PMID: 9866744
HIV-1 and HIV-2 dual infection: lack of HIV-2 provirus correlates with low CD4+ lymphocyte counts. PMID: 9468361
Human immunodeficiency virus type 2 (HIV-2) env gene analysis: prediction of glycoprotein epitopes important for heterotypic neutralization and evidence for three genotype clusters within the HIV-2a subtype. PMID: 7531216
Modulation of the NF-κB signaling pathway by the HIV-2 envelope glycoprotein and its incomplete BST-2 antagonism. PMID: 29028477
Molecular epidemiology of dual HIV-1/HIV-2 seropositive adults from Senegal, West Africa. PMID: 12908935
Population dynamics of HIV-2 in rural West Africa: comparison with HIV-1 and ongoing transmission at the heart of the epidemic. PMID: 23032414
Epitope mapping of broadly neutralizing HIV-2 human monoclonal antibodies. PMID: 22933274
HIV-2 CRF01_AB: first circulating recombinant form of HIV-2. PMID: 20502347
Slow Receptor Binding of the Noncytopathic HIV-2UC1 Envs Is Balanced by Long-Lived Activation State and Efficient Fusion Activity. PMID: 32521274
Antigenic and immunogenic sites of HIV-2 glycoproteins. PMID: 8452654
HIV-2 interaction with cell coreceptors: amino acids within the V1/V2 region of viral envelope are determinant for CCR8, CCR5 and CXCR4 usage. PMID: 25421818
Molecular analyses of HIV-1 group O and HIV-2 variants from Africa. PMID: 9209322
An ancestral HIV-2/simian immunodeficiency virus peptide with potent HIV-1 and HIV-2 fusion inhibitor activity. PMID: 23324659
Cross-reactivity on western blots in HIV-1 and HIV-2 infections. PMID: 1892591
An HIV type 2 DNA vaccine induces cross-reactive immune responses against HIV type 2 and SIV. PMID: 9430248
Cross-Reactive Antibodies With the Capacity to Mediate HIV-1 Envelope Glycoprotein-Targeted Antibody-Dependent Cellular Cytotoxicity Identified in HIV-2-Infected Individuals. PMID: 30715363
HIV-2 amino acid substitutions in Gag and Env proteins occurring simultaneously with viral load upsurge in a drug-naïve patient. PMID: 18622680
Human immunodeficiency virus type 2 (HIV-2)/HIV-1 envelope chimeras detect high titers of broadly reactive HIV-1 V3-specific antibodies in human plasma. PMID: 19019969
Comparison of alternative interpretive criteria for the HIV-1 Western blot and results of the Multispot HIV-1/HIV-2 Rapid Test for classifying HIV-1 and HIV-2 infections. PMID: 21993309
HIV-2 genetic evolution in patients with advanced disease is faster than that in matched HIV-1 patients. PMID: 20463072
Human immunodeficiency virus (HIV) type-1, HIV-2 and simian immunodeficiency virus Nef proteins. PMID: 20594957
Highly attenuated HIV type 2 recombinant poxviruses, but not HIV-2 recombinant Salmonella vaccines, induce long-lasting protection in rhesus macaques. PMID: 7492438
Genomic divergence of HIV-2 from Ghana. PMID: 2611042
Kinetic studies of HIV-1 and HIV-2 envelope glycoprotein-mediated fusion. PMID: 17144914
Role of human immunodeficiency virus (HIV)-specific T-cell immunity in control of dual HIV-1 and HIV-2 infection. PMID: 17582003
A microELISA system for the detection of both anti-HIV-1 and anti-HIV-2 antibodies. PMID: 2040818
For research use only. Not for human or drug use.
